Merck & Co., Inc. (MRK)

NYSE: MRK · Real-Time Price · USD
118.64
+0.35 (0.30%)
At close: Sep 18, 2024, 4:00 PM
118.97
+0.33 (0.28%)
After-hours: Sep 18, 2024, 7:25 PM EDT
0.30%
Market Cap 300.73B
Revenue (ttm) 62.48B
Net Income (ttm) 13.74B
Shares Out 2.53B
EPS (ttm) 5.39
PE Ratio 22.03
Forward PE 13.90
Dividend $3.08 (2.60%)
Ex-Dividend Date Sep 16, 2024
Volume 9,605,161
Open 118.20
Previous Close 118.29
Day's Range 117.87 - 119.37
52-Week Range 99.14 - 134.63
Beta 0.40
Analysts Buy
Price Target 134.58 (+13.44%)
Earnings Date Oct 24, 2024

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]

Sector Healthcare
Founded 2000
Employees 72,000
Stock Exchange NYSE
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $134.58, which is an increase of 13.44% from the latest price.

Price Target
$134.58
(13.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK) Bank of America Global Healthcare Conference September 18, 2024 6:40 AM ET Company Participants Joseph Romanelli - President, Human Health International Peter Dannenbaum ...

19 hours ago - Seeking Alpha

Merck wins first FDA approval for Keytruda as a treatment for mesothelioma

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with ...

22 hours ago - Market Watch

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,...

23 hours ago - Business Wire

Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial

Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.

1 day ago - Reuters

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

LONDON--(BUSINESS WIRE)---- $MRK #Biotech--Summit Therapeutics' Breakthrough with Ivonescimab The recent breakthrough with Summit Therapeutics' Ivonescimab (SMT112) reverberated not just in the medica...

2 days ago - Business Wire

Buy 9 Sustainable Dividend Dogs From Barron's August 100

Calvert Research and Management evaluated 1,000 large companies on 230 ESG indicators to rank the top 100 most sustainable companies for Barron's annual list. Nine dividend-paying ESG companies, inclu...

Other symbols: AGRBACBENCFGELESHAS
3 days ago - Seeking Alpha

Ten-Year Data for Merck's KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYN...

3 days ago - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA in Combination With TACE Significantly Improved PFS Compared to TACE Alone in Patients With Unresectable, Non-Metastat...

4 days ago - Business Wire

Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA® Plus CRT Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer.

4 days ago - Business Wire

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA plus trastuzumab and chemotherapy OS results as first-line treatment in patients with HER2-positive advanced gastric or GEJ adenocarcinoma.

5 days ago - Business Wire

Merck Appears Ready To Return To June Highs (Technical Analysis)

Merck's 15% decline in July is presenting investors with an intermediate to long-term buying opportunity. Long-term trend lines and Bollinger Bands indicate strong support at $110. We expect Merck to ...

5 days ago - Seeking Alpha

Trade It or Fade It: The week's big biotech moves

Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.

Other symbols: BNTXSMMT
5 days ago - CNBC Television

Merck Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced presentations showcasing the long-term safety prof...

6 days ago - Business Wire

Merck to Participate in the Bank of America 2024 Global Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bank of America 2024 Global Healthcare Conference.

7 days ago - Business Wire

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males.

7 days ago - Business Wire

BA Reaches Union Deal, COST Price Target Hike, MRK Down as SMMT Rallies

A tentative deal between Boeing (BA) and the International Aerospace Machinists union could avoid a strike. Costco (COST) receives another price target hike.

Other symbols: BACOSTSMMT
9 days ago - Schwab Network

Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's ...

Other symbols: SMMT
9 days ago - Market Watch

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half

Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.

Other symbols: SMMT
9 days ago - Benzinga

Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial

Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the market leader.

10 days ago - Barrons

Buy 3 September Dogs Of The Dow; Watch 6

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors

12 days ago - Seeking Alpha

Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 2:35 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President of Merck Resear...

12 days ago - Seeking Alpha

Why Did Merck Stock Rise 65%?

Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period.

12 days ago - Forbes

Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candida...

14 days ago - Business Wire

Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced t...

14 days ago - Business Wire

Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street

Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.

Other symbols: GILD
15 days ago - Benzinga